Drug cocktail may help radioactive iodine work better in tough thyroid cancers
NCT ID NCT06440850
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests whether two targeted drugs, vemurafenib and cobimetinib, can make thyroid cancer cells more responsive to radioactive iodine therapy. The study enrolls 21 adults with high-risk, BRAF-mutated thyroid cancer who have not yet received radioactive iodine. Participants take the drugs before their first radioactive iodine treatment to see if it improves cancer control.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- vemurafenib and cobimetinib
- What this could lead to
- If successful, this approach could make radioactive iodine therapy more effective for high-risk thyroid cancer patients with a BRAF mutation, potentially reducing cancer recurrence.
- What could go wrong
- This is a small, early-phase trial with only 21 participants, so results may not apply to everyone. The drugs can cause side effects like skin issues, fatigue, and liver problems.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BRAFV600E MUTATED HIGH-RISK DIFFERENTIATED THYROID CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
City of Hope Medical Center
RECRUITINGDuarte, California, 91010, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A radioactive clue that could spare thousands from thyroid surgery
- New online tool aims to ease cancer worry in young adults
- Coaching boosts thyroid cancer recovery
- New scan could spot hidden thyroid cancer better
- New drug cocktail shows promise for Hard-to-Treat thyroid cancer
- Targeted drug before surgery shows promise for RET-Altered thyroid cancer